177 related articles for article (PubMed ID: 38265424)
1. Heparan sulfate promotes TRAIL-induced tumor cell apoptosis.
Luo Y; Hao H; Wang Z; Ong CY; Dutcher R; Xu Y; Liu J; Pedersen LC; Xu D
Elife; 2024 Jan; 12():. PubMed ID: 38265424
[TBL] [Abstract][Full Text] [Related]
2. Heparan sulfate promotes TRAIL-induced tumor cell apoptosis.
Luo Y; Hao H; Wang Z; Ong C; Dutcher R; Xu Y; Liu J; Pedersen LC; Xu D
bioRxiv; 2023 Nov; ():. PubMed ID: 37546770
[TBL] [Abstract][Full Text] [Related]
3. An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity.
Guillaume YC; Lethier L; André C
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov; 1036-1037():142-148. PubMed ID: 27750195
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
5. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
[TBL] [Abstract][Full Text] [Related]
7. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
Jang JY; Jeon YK; Choi Y; Kim CW
Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
[TBL] [Abstract][Full Text] [Related]
8. Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.
Beyrath J; Chekkat N; Smulski CR; Lombardo CM; Lechner MC; Seguin C; Decossas M; Spanedda MV; Frisch B; Guichard G; Fournel S
Oncotarget; 2016 Oct; 7(40):64942-64956. PubMed ID: 27409341
[TBL] [Abstract][Full Text] [Related]
9. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
Di X; Zhang G; Zhang Y; Takeda K; Rivera Rosado LA; Zhang B
Oncotarget; 2013 Sep; 4(9):1349-64. PubMed ID: 23988408
[TBL] [Abstract][Full Text] [Related]
11. Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways.
Berg D; Stühmer T; Siegmund D; Müller N; Giner T; Dittrich-Breiholz O; Kracht M; Bargou R; Wajant H
FEBS J; 2009 Dec; 276(23):6912-27. PubMed ID: 19895579
[TBL] [Abstract][Full Text] [Related]
12. DR4-Ser424
Lee H; Oh Y; Jeon YJ; Lee SY; Kim H; Lee HJ; Jung YK
Cancer Res; 2019 Jun; 79(11):2839-2852. PubMed ID: 30987996
[TBL] [Abstract][Full Text] [Related]
13. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway.
Vondálová Blanárová O; Jelínková I; Szöor A; Skender B; Soucek K; Horváth V; Vaculová A; Andera L; Sova P; Szöllosi J; Hofmanová J; Vereb G; Kozubík A
Carcinogenesis; 2011 Jan; 32(1):42-51. PubMed ID: 21037225
[TBL] [Abstract][Full Text] [Related]
15. Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5.
Fei HR; Yuan C; Wang GL; Zhao Y; Li ZJ; Du X; Wang FZ
Phytomedicine; 2019 Sep; 62():152950. PubMed ID: 31102888
[TBL] [Abstract][Full Text] [Related]
16. Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells.
De Miguel D; Gallego-Lleyda A; Ayuso JM; Pawlak A; Conde B; Ochoa I; Fernández LJ; Anel A; Martinez-Lostao L
Recent Pat Anticancer Drug Discov; 2016; 11(2):197-214. PubMed ID: 26924736
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
18. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
19. Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.
Bosman MC; Reis CR; Schuringa JJ; Vellenga E; Quax WJ
J Biol Chem; 2014 Jan; 289(2):1071-8. PubMed ID: 24280212
[TBL] [Abstract][Full Text] [Related]
20. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
Gasparian ME; Chernyak BV; Dolgikh DA; Yagolovich AV; Popova EN; Sycheva AM; Moshkovskii SA; Kirpichnikov MP
Apoptosis; 2009 Jun; 14(6):778-87. PubMed ID: 19412666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
